Jaguar Health Completes Effectiveness Trial for Chemotherapy Diarrhea Treatment

Got story updates? Submit your updates here. ›

Jaguar Health, a pharmaceutical company, has announced the completion of a 28-day effectiveness trial for its drug crofelemer as a treatment for chemotherapy-induced diarrhea. The trial was designed to evaluate the use of crofelemer tablets in reducing the severity and incidence of diarrhea in cancer patients receiving the targeted therapy neratinib, which is known to cause significant diarrhea as a side effect.

Why it matters

Chemotherapy-induced diarrhea is a common and debilitating side effect that can lead to dehydration, electrolyte imbalances, and even treatment delays or discontinuation. Effective treatments for this condition are needed to improve the quality of life for cancer patients undergoing chemotherapy.

The details

The 28-day study in dogs receiving neratinib was intended to provide scientific rationale for the use of crofelemer tablets in reducing the severity and incidence of diarrhea in cancer patients receiving neratinib, a targeted therapy known to cause significant diarrhea. Topline results from the trial are expected within the next month and may complement the positive results of a previous study of crofelemer for the treatment of cancer therapy-induced diarrhea in dogs.

• The 28-day study in dogs receiving neratinib was completed in April 2026.
• Topline results from the trial are expected within the next month.

What’s next

Jaguar Health expects to receive the topline results from the effectiveness trial within the next month, which may provide additional support for the use of crofelemer in treating chemotherapy-induced diarrhea.